Liposomal Irinotecan and Apatinib
Phase 2Small molecule
Liposomal Irinotecan and Apatinib is one of 43 small molecule programs targeting Breast Cancer. It is currently in Phase 2.
3
Indications
4
Total Trials
3
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Duragesic
CCephalon
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Bisphosphonate
AmgenPreclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Postoperative Analgesia1 trial
Effect of Local Infiltration of Liposomal Bupivacaine on Postoperative Analgesia in Patients With Craniotomy Microvascular Decompression
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07245290·100 enrolled
Breast Cancer1 trial
Apatinib1 trial
Liposomal Irinotecan and Apatinib in ES-SCLC
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06749691·30 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details